Recently, a number of companies in the VDS industry have released their 2023 performance forecasts, and "pre-happiness" has become the main keynote. Among them, Tomson By-Health's revenue forecast shows that it is expected that Tomson By-Health will achieve a net profit attributable to the parent company of 15 in 202394-18.7.1 billion yuan, a year-on-year increase of 15%-35%; It is expected to achieve a net profit of 1424-17.2.1 billion yuan, a year-on-year increase of 35%-25.1%。From the record high of the semi-annual report to the forecast of the annual financial report, it can be seen that the revenue of Tomson By-Health has been steadily increasing, and Tomson By-Health has once again proved its solid position as an industry leader and its own development resilience with its strength.
Since the implementation of the "Healthy China" national strategy, the public's demand for health has been escalating. In recent years, due to the impact of the new crown, the focus of the global healthcare system is shifting from simple health management to prevention-oriented, which has promoted in-depth research in the field of nutrition and health. As a leading enterprise in the global nutrition industry, By-Health has been continuously in-depth scientific research on nutrition and health, focusing on "new raw materials, new functions and new technologies", driving product power with scientific and technological strength, constantly tapping the incremental market, and successively announcing a number of major R&D achievements, insisting on "scientific nutrition" to help the public live a healthy life.
For example, in terms of cardiovascular health, By-Health has intensified its research on the natural "vascular scavenger" light loxin, revealing a new mechanism of light loxin in the authoritative scientific journal "Frontiers in Nutrition" in September 2022, and in November, the scientific research team further determined the regulatory effect of light loon on platelet function in middle-aged and elderly people, and published the research results in the professional journal "Journal of Functional Foods".
In terms of anti-aging, By-Health cooperated with a number of professional scientific research institutions such as the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, and finally discovered the "precise removal of senescent cells" PCC1 (proanthocyanidins C1) from a specific grape seed extract, which used PCC1 alone on aging mice to help them prolong their healthy median life642%, in the future, PCC1 is expected to be used in anti-aging and aging control related fields, and the research results have been successfully published in the international authoritative journal "Nature".
Of course, not only the above kinds of research, but also the performance of Tomson By-Health in the fields of diabetes nutrition intervention and probiotic strain development is also very outstanding. It is reported that as of the end of June 2023, By-Health has obtained 370 patents, including 103 invention patents for raw materials and formulas, and 139 health food approval certificates.
Firm scientific nutrition strategy is an important way for Tomson By-Health to achieve sustainable development, and the correctness of this strategy has been preliminarily verified in the data of the 2023 Tomson By-Health revenue forecast. Nowadays, China's VDS industry is in a period of opportunity to transform from quantitative accumulation to qualitative improvement, and Tomson Bio-Health will continue to seize the opportunity to continue to make efforts in all aspects of scientific research and technology and production and operation, leading the brand and industry to a higher level of development.